CADRENAL THERAPEUTICS INC (CVKD) Stock Price, Forecast & Analysis
NASDAQ:CVKD • US1276362076
CVKD Key Statistics, Chart & Performance
The current stock price of CVKD is 8.49 USD. In the past month the price increased by 13.81%. In the past year, price decreased by -55.32%.
CVKD Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to CVKD. When comparing the yearly performance of all stocks, CVKD is a bad performer in the overall market: 89.82% of all stocks are doing better.
CVKD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CVKD. While CVKD seems to be doing ok healthwise, there are quite some concerns on its profitability.
CVKD Financial Highlights
Over the last trailing twelve months CVKD reported a non-GAAP Earnings per Share(EPS) of -8.01. The EPS decreased by -19.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -351.94% | ||
| ROE | -525.99% | ||
| Debt/Equity | 0 |
CVKD Forecast & Estimates
7 analysts have analysed CVKD and the average price target is 36.38 USD. This implies a price increase of 328.5% is expected in the next year compared to the current price of 8.49.
CVKD Ownership
CVKD Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.34 | 966.197B | ||
| JNJ | JOHNSON & JOHNSON | 21.32 | 586.592B | ||
| MRK | MERCK & CO. INC. | 22.88 | 296.105B | ||
| PFE | PFIZER INC | 9.21 | 154.083B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.25 | 124.384B | ||
| ZTS | ZOETIS INC | 19.09 | 57.184B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.91 | 26.184B | ||
| VTRS | VIATRIS INC | 5.9 | 17.564B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.25 | 13.013B | ||
| AXSM | AXSOME THERAPEUTICS INC | 200.12 | 8.226B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CVKD
Company Profile
Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. The company is headquartered in Ponte Vedra, Florida and currently employs 4 full-time employees. The company went IPO on 2023-01-20. The company has three clinical-stage assets: VLX-1005, a first-in-class Phase 2 12-LOX Inhibitor for patients with HIT; tecarfarin, an oral vitamin K antagonist (VKA) for chronic use in patients with kidney dysfunction or left ventricular assist devices (LVADs), and frunexian, a parenteral small-molecule Factor XIa antagonist for use in acute hospital settings. Its product candidate, tecarfarin, is a late-stage, reversible oral VKA in the same drug class as warfarin, designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Its frunexian is a small molecule fast-on, fast-off parenteral Phase II-ready potent intravenous (IV) Factor XIa inhibitor designed for acute care settings, especially where contact activation of coagulation by medical devices or artificial surfaces plays a significant role.
Company Info
CADRENAL THERAPEUTICS INC
822 A1a North, Suite 306
Ponte Vedra FLORIDA US
Employees: 4
Phone: 19043000701
CADRENAL THERAPEUTICS INC / CVKD FAQ
What does CADRENAL THERAPEUTICS INC do?
Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. The company is headquartered in Ponte Vedra, Florida and currently employs 4 full-time employees. The company went IPO on 2023-01-20. The company has three clinical-stage assets: VLX-1005, a first-in-class Phase 2 12-LOX Inhibitor for patients with HIT; tecarfarin, an oral vitamin K antagonist (VKA) for chronic use in patients with kidney dysfunction or left ventricular assist devices (LVADs), and frunexian, a parenteral small-molecule Factor XIa antagonist for use in acute hospital settings. Its product candidate, tecarfarin, is a late-stage, reversible oral VKA in the same drug class as warfarin, designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Its frunexian is a small molecule fast-on, fast-off parenteral Phase II-ready potent intravenous (IV) Factor XIa inhibitor designed for acute care settings, especially where contact activation of coagulation by medical devices or artificial surfaces plays a significant role.
What is the stock price of CADRENAL THERAPEUTICS INC today?
The current stock price of CVKD is 8.49 USD. The price increased by 1.31% in the last trading session.
What is the dividend status of CADRENAL THERAPEUTICS INC?
CVKD does not pay a dividend.
What is the ChartMill technical and fundamental rating of CVKD stock?
CVKD has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Who owns CADRENAL THERAPEUTICS INC?
You can find the ownership structure of CADRENAL THERAPEUTICS INC (CVKD) on the Ownership tab.